Clinical evaluation of antianginal effects of a single dose of nilvadipine(FK235) with serial multistage treadmill exercise testing. A randomised double-blind cross-over study in comparison with placebo
| Autor: | Jitsuki Tsuzuki, Atsushi Ito, Haruo Hirayama, Sadao Oguchi, Masato Tsuzuki, Iwao Sotobata, Mitsuyoshi Nakashima, Hitomi Miyagaki, Teruo Kondo, Shoji Noda, Haruo Inagaki |
|---|---|
| Rok vydání: | 1987 |
| Předmět: | |
| Zdroj: | Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 18:393-405 |
| ISSN: | 1882-8272 0388-1601 |
| DOI: | 10.3999/jscpt.18.393 |
| Popis: | In order to investigate the antianginal effects of a new calcium antagonist, nilvadipine, a randomized double-blind cross-over study controlled with placebo wascarried out in 15 patients with stable effort angina pectoris. Multistage treadmillexercise testing was performed before, and at 2, 4, and 7 hours after a single oraladministration of 6 mg nilvadipine or placebo. The exercise testing was terminated atmoderate anginal pain.The treadmill exercise duration showed no statistically significant time effects ororder effects either before or after administration of the test drugs. Before administration, there were no significant differences in exercise duration, time to onset of STsegment depression≥0.1 mV, pressure-rate products, or ST deviation between nilvadipine and placebo.Nilvadipine significantly prolonged exercise duration at 2, 4, and 7 hours after dosing, and time to onset of ST-segment depression≥0.1 mV at 2 and 4 hours after dosing.However, there were no significant differences in ST deviation at peak exercise betweennilvadipine and placebo.Nilvadipine significantly reduced resting systolic blood pressure at 2 and 4 hoursafter dosing. At peak exercise, nilvadipine significantly increased heart rate at 2 and 7hours, and pressure-rate product at 2 hours after dosing, respectively.These results indicate that nilvadipine significantly increases exercise tolerance inpatients with stable effort angina pectoris up to 7 hours after a single oral administrationof 6 mg. It is concluded that nilvadipine is a clinically useful antianginal agent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|